✦ LIBER ✦

275 Mechanism of drug resistance in hepatitis C: The case of protease inhibitor BILN-2061

Book ID: 117373787
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 247 KB
Volume: 42
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(05)81687-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Short-term antiviral efficacy of BILN 20

Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients

✍ Holger Hinrichsen; Yves Benhamou; Heiner Wedemeyer; Markus Reiser; Roel E. Sentj 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 182 KB

Antiviral efficacy of NS3-serine proteas

Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C

✍ Markus Reiser; Holger Hinrichsen; Yves Benhamou; Henk W. Reesink; Heiner Wedemey 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 196 KB

The design of a potent inhibitor of the

The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061—From the NMR tube to the clinic

✍ Youla S. Tsantrizos 📂 Article 📅 2004 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 858 KB

## Abstract The virally encoded serine protease NS3/NS4A is essential to the life cycle of the hepatitis C virus (HCV), an important human pathogen causing chronic hepatitis, cirrhosis of the liver, and hepatocellular carcinoma. Until very recently, the design of inhibitors for the HCV NS3 protease

Structure−Activity Study on a Novel Seri

Structure−Activity Study on a Novel Series of Macrocyclic Inhibitors of the Hepatitis C Virus NS3 Protease Leading to the Discovery of BILN 2061

✍ Llinàs-Brunet, Montse; Bailey, Murray D.; Bolger, Gordon; Brochu, Christian; Fau 📂 Article 📅 2004 🏛 American Chemical Society 🌐 English ⚖ 77 KB

136 Antiviral effect of BILN 2061, a nov

136 Antiviral effect of BILN 2061, a novel HCV serine protease inhibitor, after oral treatment over 2 days in patients with chronic hepatitis C, non-genotype 1

✍ Markus Reiser; Holger Hinrichsen; Yves Benhamou; Roel Sentjens; Heiner Wedemeyer 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 140 KB

Characterization of resistance to the pr

Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus–infected patients

✍ Simone Susser; Christoph Welsch; Yalan Wang; Markus Zettler; Francisco S. Doming 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 543 KB

Boceprevir is a hepatitis C virus (HCV) nonstructural protein (NS) 3/4A protease inhibitor that is currently being evaluated in combination with peginterferon alfa-2b and ribavirin in phase 3 studies. The clinical resistance profile of boceprevir is not characterized in detail so far. The NS3 protea